Table 2 Baseline patient characteristics in sham arm of included randomized clinical trials
SYMPLICITY HTN-3 | Desch et al. | ReSet | RADIANCE-HTN SOLO | SPYRAL HTN-OFF MED Pivotal | SPYRAL HTN-ON MED | REDUCE HTN: REINFORCE | REQUIRE | RADIANCE-HTN TRIO | |
|---|---|---|---|---|---|---|---|---|---|
Number of patients | 171 | 36 | 33 | 72 | 165 | 42 | 17 | 67 | 67 |
Age - n ± SD | 56.2 ± 11.2 | 57.4 ± 8.6 | 57.1 ± 6.6 | 53.8 ± 10 | 52.6 ± 10.4 | 53 ± 10.7 | 58.2 ± 9.8 | 55.6 ± 12.1 | 52.8 ± 9.1 |
Gender (male) - n (%) | 110 (64.3) | 25 (69) | (73) | 39 (54) | 113 (68) | 34 (81) | 13 (76) | 53 (79.1) | 53 (79) |
Race - n (%) | |||||||||
white | 119 (69.6) | 36 (100) | (97) | 52 (72) | 50 (30) | 15 (36) | 14 (82) | NR | 50 (75) |
black | 50 (29.2) | 0 | NR | 13 (18) | 31 (19) | 5 (12) | 3 (18) | NR | 12 (19) |
other | 2 (1.2) | 0 | NR | 7 (10) | 5 (3) Δ | 1 (2) ¥ | 1 (6) | NR | 3 (4.5) ‡ |
Comorbidities - n (%) | |||||||||
Chronic Kidney Disease - GFR < 60 | 17 (9.9) | NR * | (18) | 3 (4) | NR | NR | NR ** | 18 (26.9) | 7 (11) |
Diabetes Mellitus 2 | 70 (40.9) | 13 (36) | (31) | 5 (7) | 9 (5) | 8 (19) | 2 (12) | 20 (29.9) | 17 (25) |
Obstructive Sleep Apnea | 54 (31.6) | NR | (12) | 8 (11) | 12 (7) | 10 (24) | 1 (6) | 8 (11.9) | 11 (16) |
Peripheral Artery Disease | 5 (2.9) | 2 (6) | NR | NR | 0 | 0 | NR | 2 (3) | NR |
Coronary Artery Disease | 43 (25.1) | 17 (47) | (15) | NR | 8 (5) | 1 (2) | 3 (18) | 9 (13.4) | NR |
Smokers - n (%) | 21 (12.3) | 4 (11) | (15) | NR | 27 (16) | 11 (26) | 2 (12) | NR | NR |
Hyperlipidemia - n (%) | 111 (64.9) | NR | NR | NR | NR | NR | 4 (24) | 40 (59.7) | NR |
BMI (kg/m 2 ) - n ± SD | 33.9 ± 6.4 | 31.2 ± 4.6 | 28.8 ± 3.9 | 29.0 ± 5.0 | 30.9 ± 5.5 | 32.5 ± 4.6 | NR | 28.4 ± 4.5 | 32.6 ± 5.4 |
Mean number of antihypertensive agents - n ± SD | 5.2 ± 1.4 | 4.3 ± 1.3 | 4.2 ± 1.1 | 0 (OFF MED) | 0 (OFF MED) | 2.3 ± 0.8 | 0 (OFF MED) | NR | NR |